{
    "guideline_id": "2024CSCO肿瘤治疗所致血小板减少症诊疗指南-  .txt",
    "cancer_info": {
        "cancer_name": "Solid and Hematologic Tumors"
    },
    "clinical_recommendations": [
        {
            "clinical_context": "Emergency situation with platelet count <10×10⁹/L or active bleeding",
            "recommendation_type": "Treatment Plan",
            "recommendation_content": "Immediate platelet transfusion",
            "treatment_line": "",
            "biomarker_requirements": [],
            "recommendation_level": "Level I",
            "evidence_level": "Level I"
        },
        {
            "clinical_context": "Platelet count <10×10⁹/L without bleeding",
            "recommendation_type": "Treatment Plan",
            "recommendation_content": "Platelet transfusion plus rhTPO or rhIL-11",
            "treatment_line": "",
            "biomarker_requirements": [],
            "recommendation_level": "Level I",
            "evidence_level": "Level I"
        },
        {
            "clinical_context": "Platelet count 10~75×10⁹/L without bleeding",
            "recommendation_type": "Treatment Plan",
            "recommendation_content": "rhTPO (300 U/kg daily) or rhIL-11 (25-50 μg/kg daily)",
            "treatment_line": "",
            "biomarker_requirements": [],
            "recommendation_level": "Level I",
            "evidence_level": "Level I"
        },
        {
            "clinical_context": "Platelet count 10~75×10⁹/L without bleeding",
            "recommendation_type": "Treatment Plan",
            "recommendation_content": "Combine with TPO receptor agonists (e.g., hetrombopag, avatrombopag)",
            "treatment_line": "",
            "biomarker_requirements": [],
            "recommendation_level": "Level II",
            "evidence_level": "Level II"
        },
        {
            "clinical_context": "All patients with platelet count <75×10⁹/L",
            "recommendation_type": "Treatment Plan",
            "recommendation_content": "rhTPO or rhIL-11 with or without TPO receptor agonists",
            "treatment_line": "",
            "biomarker_requirements": [],
            "recommendation_level": "Level I or II",
            "evidence_level": "Level I or II"
        },
        {
            "clinical_context": "Patients undergoing concurrent chemoradiotherapy with radiation to long bones or pelvis",
            "recommendation_type": "Treatment Plan",
            "recommendation_content": "Prophylactic use of rhTPO or rhIL-11",
            "treatment_line": "",
            "biomarker_requirements": [],
            "recommendation_level": "Level II",
            "evidence_level": "Level II"
        },
        {
            "clinical_context": "Patients with platelet reduction due to PARP inhibitors or T-DM1",
            "recommendation_type": "Treatment Plan",
            "recommendation_content": "Pause targeted therapy and administer rhTPO or rhIL-11",
            "treatment_line": "",
            "biomarker_requirements": [],
            "recommendation_level": "Level I",
            "evidence_level": "Level I"
        },
        {
            "clinical_context": "Immunotherapy patients after excluding immune thrombocytopenia (ITP) or thrombotic thrombocytopenic purpura (TTP)",
            "recommendation_type": "Treatment Plan",
            "recommendation_content": "rhTPO or rhIL-11; for severe cases, add immunoglobulin or corticosteroids",
            "treatment_line": "",
            "biomarker_requirements": [],
            "recommendation_level": "Level II",
            "evidence_level": "Level II"
        },
        {
            "clinical_context": "Secondary prevention for patients with platelet nadir <50×10⁹/L or 50-75×10⁹/L with high bleeding risk",
            "recommendation_type": "Treatment Plan",
            "recommendation_content": "rhTPO: 300 U/kg every other day starting 1-2 days after chemotherapy for 7-10 days",
            "treatment_line": "",
            "biomarker_requirements": [],
            "recommendation_level": "Level I",
            "evidence_level": "Level I"
        },
        {
            "clinical_context": "Secondary prevention for patients with platelet nadir <50×10⁹/L or 50-75×10⁹/L with high bleeding risk",
            "recommendation_type": "Treatment Plan",
            "recommendation_content": "Hetrombopag 75 mg daily orally until next chemotherapy cycle",
            "treatment_line": "",
            "biomarker_requirements": [],
            "recommendation_level": "Level II",
            "evidence_level": "Level II"
        },
        {
            "clinical_context": "General assessment for biomarker testing",
            "recommendation_type": "Biomarker Testing Guidance",
            "recommendation_content": "TPO level testing may guide medication but is not routinely recommended; genetic polymorphisms require further research",
            "treatment_line": "",
            "biomarker_requirements": [
                {
                    "biomarker_name": "TPO",
                    "status": "Not routinely recommended",
                    "testing_guidance": "May guide use of rhTPO in patients with low endogenous TPO levels"
                },
                {
                    "biomarker_name": "Genetic factors",
                    "status": "Under investigation",
                    "testing_guidance": "Not routinely recommended; polymorphisms in drug metabolism genes (e.g., for oxaliplatin) may influence risk but require further study"
                }
            ],
            "recommendation_level": "",
            "evidence_level": ""
        }
    ],
    "biomarker_clinical_significance": {
        "clinical_significance": "TPO levels may guide the use of recombinant thrombopoietin (rhTPO) but are not routinely recommended. Genetic polymorphisms in drug metabolism genes could influence the risk of chemotherapy-induced thrombocytopenia but require further research."
    },
    "tcm_recommendations": []
}